KCT0004447尚未招募未知
A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the evaluation of the efficacy and safety of CT20S on the Skin wrinkle improvement
P&K Skin Research Center0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 40(Year) 至 54(Year)（—）
- 性别
- Female
入选标准
- •1) Women over 40 years old and under 55 years old
- •2) In a visual evaluation, both left and right eye wrinkles are grade 3 or higher
- •3) Using Corneometer®, measure the amount of water in both cheeks. Left and right cheeks are less than 49AU
- •4) Those who have agreed to participate in this test prior to the start of the test and have signed a written consent form
排除标准
- •1) Those who have or are currently undergoing treatment for skin diseases such as atopic dermatitis and psoriasis
- •2) Sensitive or allergic to food ingredients for this human application test
- •3) People with abnormal skin conditions such as spots, acne, erythema, and capillary dilation in the test area
- •4) Visit 1 A person who received treatment on the facial (skin stripping, other skin care, etc.) or received treatment on the facial area within 6 months
- •5) Visitor 1 Use a skin external substance containing steroids on the facial part or take an oral retinoid/steroid agent within 3 months of the standard visit
- •6) Visitor 1 Use functional cosmetic (retinoid agent, retinol, AHA) or moisturizing cosmetic or skin care (LED mask, ion booster, etc.) to improve wrinkles within 2 weeks of visit
- •7) People who take diet pills (absorbent and antidepressants, appetite suppressants, etc.) and contraceptives or hormones or diuretics within one month based on visit1
- •8) Visitors who have taken antioxidants, hyaluronic acid, health function foods containing collagen, moon flower species freedom, vitamin A, vitamin C, vitamin E-containing medicines and health function foods within two weeks of visit1;
- •9) Visit 1 A person who has participated in other interventional clinical tests (including human application tests) within one month of the standard or plans to participate in other interventional clinical tests (including human application tests) after the start of this human application test.
- •10) Person whose AST (GOT) or ALT (GPT) is 120IU/L or higher, or whose ?-GTP is 180IU/L or higher
- •11) Those whose creatine is 2.4 mg/dl or higher
- •12) A person who is less than or equal to 0.1µIU/ml of TSH or greater than 10µIU/ml of TSH
- •13) Unregulated hypertension patients (based on measurement after 10 minutes of stabilization, at least 160mmHg of the hydraulic pressure or more than 100mmHg of the relaxant blood pressure)
- •14) Unregulated diabetics (more than 180 mg/dl per empty blood)
- •15) People with schizophrenia, depression, drug addiction, etc.
- •16) Those who are pregnant, nursing, or planning to conceive within three months;
- •17) Those who are in hospital, drug treatment, and rehabilitation for alcohol use ·Distribution disorder, heart disease, and central nervous disorder
- •18) Smokers or those who smoke less than a year after quitting smoking
- •19) A person who judges that the tester is inappropriate for this test
研究者
相似试验
招募中
不适用
Clinical Trial for the evaluation of the efficacy and safety of 7-MEGATM500 on the Skin wrinkle improvementDiseases of the skin and subcutaneous tissueKCT0004592Vitech90
已完成
不适用
A Clinical Trial for the evaluation of the efficacy and safety of RW0117 on dyspepsiaKCT0005265Richwood Trading Company, LTD.100
招募中
不适用
The Efficacy and Safety of KD501 on Memory ImprovementKCT0004424Wonkwang University. Iksan Korean Medicine Hospital80
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisEUCTR2017-002177-20-ATAllergan Ltd.311
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersDiabetic GastroparesisEUCTR2017-002177-20-ROAllergan Ltd.311